Telix Pharmaceuticals Signs Dual Collaboration Agreements with EDAP and Profound to Expand PSMA-PET Imaging into Ablative Prostate Cancer Workflows

Telix Pharmaceuticals' letters of intent with EDAP TMS and Profound Medical signal a deliberate push to embed PSMA-PET imaging into ablative prostate cancer workflows — a move that will test both the regulatory boundaries of approved indications and the supply readiness of kit-based gallium-68 production at scale.

Announced 15 May 2026, the collaborations centre on Telix's two gallium Ga-68 gozetotide agents, Gozellix and Illuccix, both supplied as preparation kits under existing FDA clearance. The intended use cases — patient selection, treatment planning, and post-treatment monitoring alongside robotic HIFU (Focal One) and transurethral ultrasound ablation (TULSA) — fall outside current approved indications. Telix has acknowledged that PSMA-PET imaging is not presently cleared for treatment-planning indications associated with these therapies, framing all collaborative activity as non-promotional scientific and research engagement.

For QA directors and regulatory affairs leads, that distinction carries weight. Any evidence generated under these letters of intent will need to be managed within a framework that separates investigational use from commercial promotion, consistent with 21 CFR Part 312 requirements for investigational new drug applications if formal clinical studies proceed. The safety disclosures accompanying the announcement reiterate known interpretation risks: a negative Gozellix PET does not exclude prostate cancer, and gallium Ga-68 gozetotide uptake is not cancer-specific.

On the manufacturing side, the kit-based format of both agents offers a degree of supply-chain flexibility that centralised cyclotron-produced radiopharmaceuticals do not. Gallium-68 generator or accelerator-based kits can be prepared at distributed sites under GMP conditions, reducing last-mile logistics constraints that have historically limited PET tracer availability in community and regional oncology settings. Broader adoption across HIFU and TULSA centres — many of which operate outside major academic hospitals — will require Telix and its distribution network to demonstrate consistent sterility assurance and release-testing turnaround at higher volume.

EDAP Chief Executive Ryan Rhodes cited the growing global installed base of Focal One systems as a driver for standardising PSMA-PET-guided focal therapy protocols. Profound's CEO Arun Menawat pointed to emerging clinical evidence supporting imaging across whole-gland, partial-gland, and focal ablation workflows. Neither company has disclosed timelines for formal study initiation or regulatory submissions tied to these collaborations.

The pace at which evidence packages mature under these agreements will determine whether PSMA-PET imaging secures label expansions that formally support ablative treatment planning — a regulatory milestone that would materially reshape procurement and production planning for gallium-68 kit manufacturers.

Source: Telix Pharmaceuticals via corporate press release, 15 May 2026.